The fund was created in April 2017 as a private Pricaf [investment vehicle for private equity investments] and targets companies active in the treatment of chronic diseases such as inflammatory, neurodegenerative, cardiovascular disease and cancer. The fund is geared to Belgian companies as well as European "early stage" companies such as university spin-offs.
